JP3596919B2 - Method for producing high-purity optically active compounds - Google Patents
Method for producing high-purity optically active compounds Download PDFInfo
- Publication number
- JP3596919B2 JP3596919B2 JP30255694A JP30255694A JP3596919B2 JP 3596919 B2 JP3596919 B2 JP 3596919B2 JP 30255694 A JP30255694 A JP 30255694A JP 30255694 A JP30255694 A JP 30255694A JP 3596919 B2 JP3596919 B2 JP 3596919B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- group
- compound represented
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 57
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 26
- -1 benzhydryl group Chemical group 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 244000005700 microbiome Species 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 230000000813 microbial effect Effects 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- SYAGKJHUEVOHQM-NSHDSACASA-N (7r)-5-benzyl-7-hydroxy-5-azaspiro[2.4]heptan-4-one Chemical compound C([C@@H](C1(CC1)C1=O)O)N1CC1=CC=CC=C1 SYAGKJHUEVOHQM-NSHDSACASA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 0 CCC(CCN1*)C(CC)C1=O Chemical compound CCC(CCN1*)C(CC)C1=O 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JCEVTMVADBEPJS-LLVKDONJSA-N [N-]=[N+]=N[C@@H]1CN(CC2=CC=CC=C2)C(=O)C11CC1 Chemical compound [N-]=[N+]=N[C@@H]1CN(CC2=CC=CC=C2)C(=O)C11CC1 JCEVTMVADBEPJS-LLVKDONJSA-N 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Indole Compounds (AREA)
Description
【0001】
【産業上の利用分野】
本発明は、化7
【0002】
【化7】
で表される優れたキノロン誘導体(特開平2−231475号)の製造原料として有用な、式(4)
【0003】
【化8】
(式中、Rはベンジル基、トリチル基、ベンズヒドリル基または低級アルキル基を意味する。ここで置換基Rがベンゼン環を有する置換基の場合、そのベンゼン環は置換基を有していてもよい。nは2または3を表す。)
で示される光学活性なアミン化合物の製造法に関する。
【0004】
【従来の技術】
従来、式(4)で表される立体配位のアミン化合物を立体異性体的に純粋に製造する方法は特開平4−149174号に記載の如く光学活性な酒石酸との塩として得る方法(ラセミ体の分割)が知られている。しかしこの方法は塩による光学分割であり、完全な分割が可能となっても不要な立体のアミン化合物が残存することを免れ得ない。
【0005】
【発明が解決しようとする課題】
本発明の目的は、キノロン誘導体の製造原料として有用な式(4)で表される化合物(以下、化合物(4)という。他の番号の式の化合物についても同様に省略する。)について、微生物を用いた不斉還元反応によって所望の立体異性体のみを製造する方法を提供することにある。
【0006】
すなわち本発明は、式(1)
【0007】
【化9】
(式中、Rはベンジル基、トリチル基、ベンズヒドリル基または低級アルキル基を意味する。ここで置換基Rがベンゼン環を有する置換基の場合、そのベンゼン環は置換基を有していてもよい。nは2または3を表す。)
で示される化合物を、
ファエオクレオプシス属に属し不斉還元能を有する微生物の菌体、培養液または微生物菌体処理物で処理することを特徴とする、式(2)
【0008】
【化10】
(式中、Rはベンジル基、トリチル基、ベンズヒドリル基または低級アルキル基を意味する。ここで置換基Rがベンゼン環を有する置換基の場合、そのベンゼン環は置換基を有していてもよい。nは2または3を表す。)
で示される化合物の製法に関する。
【0009】
さらに本発明は、式(1)の化合物が、Rがベンジル基でありnが2もしくは3である化合物であるところの上記の製法に関する。
【0010】
また本発明は、式(1)で示される化合物を、
ファエオクレオプシス属に属し不斉還元能を有する微生物の菌体、培養液または微生物菌体処理物で処理し、
式(2)で示される化合物を得、この式(2)で示される化合物にジフェニルホスホリルアジドを作用させ、式(3)
【0011】
【化11】
(式中、Rはベンジル基、トリチル基、ベンズヒドリル基または低級アルキル基を意味する。ここで置換基Rがベンゼン環を有する置換基の場合、そのベンゼン環は置換基を有していてもよい。nは2または3を表す。)
で示される化合物を得、この式(3)で示される化合物を還元することを特徴とする式(4)
【0012】
【化12】
(式中、Rはベンジル基、トリチル基、ベンズヒドリル基または低級アルキル基を意味する。ここで置換基Rがベンゼン環を有する置換基の場合、そのベンゼン環は置換基を有していてもよい。nは2または3を表す。)
で示される化合物の製造法に関する。
【0013】
そして本発明は、式(3)で示される化合物の還元が、金属水素化アルミニウム化合物あるいはジボランによる還元である上記の製法に関する。
【0014】
さらに本発明は、式(1)の化合物が、Rがベンジル基でありnが2である化合物であるところ上記の製法に関する。
【0015】
本発明について以下に詳細に説明する。
すなわち本発明は、化合物(1)に対してファエオクレオプシス属に属する微生物から選ばれるところの不斉還元能を有する微生物を作用させ、光学活性な化合物(2)を得、更にこれをアミン化合物である化合物(4)に変換する方法に関するものである。
【0016】
本発明に使用される式(1)で示される化合物において置換基Rは、ベンジル基、トリチル基、ベンズヒドリル基または低級アルキル基を意味する。ここでRが部分構造としてベンゼン環を有するベンジル基、トリチル基、ベンズヒドリル基であるとき、そのベンゼン環はさらに置換基を有していてもよい。ベンゼン環が複数ある場合、1以上のベンゼン環が置換されていてもよい。またベンゼン環1に対して置換基は1種以上が1以上置換していてもよい。このようなベンゼン環上の置換基としては、メチル基、エチル基、プロピル基、ブチル基、ペンチル基またはヘキシル基等のアルキル基類、メトキシル基、エトキシル基、プロポキシル基、ブトキシル基、ペントキシル基、ヘキシルオキシ基等のアルコキシル基類、ハロゲン原子類、およびニトロ基からなる群から選ばれる置換基でよい。式(1)で示される化合物は既知の方法によって調製することができる(特開平3−95176号公報、特開平5−286933号公報参照)。
【0017】
本発明の方法によって化合物(1)から化合物(2)を製造するには、市販のファエオクレオプシス属(Phaeocreopsis sp.)に属する微生物であって、不斉還元能を有する微生物を使用して製造すればよい。この方法にはファエオクレオプシス属に属する微生物の菌体、培養液または微生物菌体処理物が使用できる。
【0018】
微生物の菌体とは、培養液から遠心分離、濾過等により集菌された生菌体、あるいは、真空乾燥菌体、凍結乾燥菌体および有機溶媒による乾燥菌体等の乾燥菌体などである。また、菌体を公知の方法によって水不溶の担体(例えば、アクリルアミドゲル)などに固定化したものを使用してもよい。
【0019】
微生物の培養液とは、当該微生物を適当な培地で培養したもので、増殖した微生物菌体およびその代謝物を含むものである。
【0020】
微生物菌体処理物は、微生物菌体の抽出物や微生物菌体の磨砕物、微生物菌体を超音波処理ものや、さらには、それらをクロマトグラフィー、濾過等の公知の方法により分画し、本発明の不斉還元の処理に必要な成分を分離したものである。なお、この分画物に含まれる処理に必要な成分は完全に純粋な状態でなくともよく、反応に障害とならないのであれば他の成分を含んでいてもよい。
【0021】
本発明の方法によって式(2)で表される化合物を製造する方法について述べる。すなわち、まず式(1)で表される化合物を適当な緩衝液に懸濁し、次いでファエオクレオプシス属する微生物の菌体、培養物または処理物を加え、撹拌して処理することによって行えばよい。
【0022】
この処理に際して、処理温度は通常5℃から60℃の範囲であればよいが、好ましくは20℃から40℃の範囲である。処理液のpHは4から9の範囲であればよく、好ましくはpH5から7の範囲である。処理時間は、通常、1日から3日間であり、処理液を撹拌して行えばよい。
【0023】
処理液中で使用されるところの式(1)で表される化合物の濃度は、0.1%から5%の間であればよいが、0.1%から0.5%の範囲が特に好ましい。微生物の培養液、微生物菌体または微生物菌体処理物の使用量は特に限定されないが、乾燥菌体重量に換算して、化合物(1)に対し重量比で 0.2倍から2倍が適当である。
【0024】
上記の処理の終了後、処理液を濾過して菌体を除去した後、濾液から抽出、減圧濃縮等の通常の操作を用いることによって目的の化合物(2)を単離することができる。
【0025】
化合物(2)をアジド化合物である化合物(3)に変換するにはジフェニルホスホリルアジドを反応させる方法によるのが簡便である。本発明ではこの試薬で通常使用される反応条件を用いて実施すればよい。
【0026】
この化合物(3)を化合物(4)に変換するための還元は、リチウム アルミニウム ハイドライド、ナトリウム ビス(2−メトキシエトキシ)アルミニウムハイドライド等の金属水素化アルミニウム化合物あるいはジボラン等の水素化ホウ素化合物を使用して行い、化合物(3)のアミド部分とアジド部分とを同時に還元すればよい。
【0027】
【実施例】
以下に、本発明を実施例あるいは参考例によって具体的に説明するが、本発明はこれらに限定されるものではない。
【0028】
[参考例1]
ブドウ糖4%、ペプトン1%、リン酸水素二カリウム0.1%、リン酸二水素カリウム0.1%からなる液体培地(pH 6.0)、 100 ml を坂口フラスコに分注し、オートクレーブにて加熱滅菌した。フラスコの培地にファエオクレオプシス属の種菌(JCM 1880)を接種し、30℃で2晩振とう培養して菌体培養液を得た。
【0029】
[実施例1] (R)−5− ベンジル −7− ヒドロキシ −4− オキソ −5− アザスピロ [2.4] ヘプタンの製造
5−ベンジル−4,7− ジオキソ−5− アザスピロ[2.4] ヘプタン 300 mg を上記参考例で得た培養液 300 ml に懸濁し、3日間撹拌した。反応液に酢酸エチル 100 ml を加えセライト濾過により菌体を除いた。水層を更に酢酸エチル 100 ml で2回抽出し有機層を乾燥後、溶媒を溜去した。残査をシリカゲルクロマトグラフィ−に供することにより目的物 195 mg (光学純度 99%ee)を得た。尚、光学異性体の分析はHPLCを用いて行った。
【0030】
・使用カラム:キラルセルOJ(ダイセル化学工業株式会社製)
・移動相:n−ヘキサン:イソプロパノ−ル=10:1
・流速:0.8 ml / min、波長:230 nm
【0031】
1H−NMR(CDCl3) δ:
0.88 − 1.18(4H, m), 3.12 − 3.63(3H, m), 3.93 − 4.06(1H, m), 4.45(2H, d, J = 2 Hz), 7.19 − 7.35(5H, m).
【0032】
[実施例2] (R)−6− ベンジル −8− ヒドロキシ −5− オキソ −6− アザスピロ [3.4] オクタンの製造
6−ベンジル−5,8− ジオキソ−6− アザスピロ[3.4] オクタン 100 mg を上記参考例で得た培養液 100 ml に懸濁し、24時間撹拌した。反応液に酢酸エチル 50 mlを加えセライト濾過により菌体を除いた。水層を更に酢酸エチル 50 mlで2回抽出し有機層を乾燥後、溶媒を溜去した。残査をシリカゲルクロマトグラフィ−に供することにより目的物 80 mg(光学純度 99%ee)を得た。尚、光学異性体の分析は実施例1と同様HPLCを用いて行った。
【0033】
1H−NMR(CDCl3) δ:
1.82 − 1.61(6H, m), 3.24 − 3.69(3H, m), 3.96 − 4.11(1H, m), 4.59(2H, d, J = 2 Hz), 7.15 − 7.40(5H, m).
【0034】
[実施例3] (S)−7− アジド −5− ベンジル −4− オキソ −5− アザスピロ [2.4] ヘプタンの製造
アゾジカルボン酸ジエチル 230 mg とトリフェニルホスフィン 340 mg を無水テトラヒドロフラン 5 ml に溶解し、氷冷下30分間撹拌した。次いで、(R)−5−ベンジル−7− ヒドロキシ−4− オキソ−5− アザスピロ[2.4] ヘプタン 220 mg とジフェニルホスホリルアジド 360 mg を無水テトラヒドロフランに溶解した溶液を滴下し一晩撹拌した。溶媒を溜去して残査をシリカゲルクロマトグラフィ−に供することにより標記の化合物 150 mg を油状化合物として得た。
【0035】
1H−NMR(CDCl3) δ:
0.85 − 1.51(4H, m), 3.23 − 3.83(3H, m), 4.60(2H, d, J = 3 Hz), 7.26 − 7.30(5H, m).
IR(KBr): 2100 cm−1(N3)
【0036】
[実施例4] (S)−7− アミノ −5− ベンジル −5− アザスピロ [2.4] ヘプタンの製造リチウムアルミニウムハイドライド テトラヒドロフラン溶液(1.0 M / L )3 mlに氷冷撹拌下(S)−7−アジド−5− ベンジル−4− オキソ−5− アザスピロ[2.4] ヘプタン 140 mg を無水テトラヒドロフラン 5 ml に溶解して滴下し、加熱還流下で1時間撹拌した。反応液を氷冷し水 0.2 ml、 10%水酸化ナトリウム水溶液 0.2 ml を滴下し室温で30分間撹拌した。不溶物を濾過により除き、濾液を濃縮後残査をシリカゲルクロマトグラフィ−に供することにより標記の化合物 92 mg(光学純度 98%ee)を得た。尚、光学異性体の分析は、アミンをジニトロベンゾイル体に誘導後HPLCを用いて行った。
【0037】
・使用カラム:スミキラル OA−4600(住友化学工業株式会社製)
・移動相:n−ヘキサン:エチレンジクロリド:エタノ−ル:トリフルオロ酢酸= 80 : 20 : 5 : 0.2
・流速:1.2 ml / min, 波長:254 nm
【0038】
1H−NMR(CDCl3) δ:
0.26 − 0.96(4H, m), 2.20 − 3.16(5H, m), 3.61(2H, s), 7.33(5H, bs)
【0039】
【発明の効果】
本発明の方法は、緩和な条件下で反応を行わせることができ、しかも反応時に副反応がほとんど生じないため高純度の光学活性な化合物(2)を得ることができる。さらに、得られた化合物(2)は化合物(3)を経由して化合物(4)に容易に誘導することができる。[0001]
[Industrial applications]
The present invention provides
[0002]
Embedded image
Formula (4) useful as a raw material for producing an excellent quinolone derivative represented by the formula (JP-A-2-231475)
[0003]
Embedded image
(In the formula, R represents a benzyl group, a trityl group, a benzhydryl group or a lower alkyl group. When the substituent R is a substituent having a benzene ring, the benzene ring may have a substituent. .N represents 2 or 3.)
And a method for producing an optically active amine compound represented by the formula:
[0004]
[Prior art]
Conventionally, a method for producing a stereoisomerically pure amine compound represented by the formula (4) in a stereoisomerically pure manner has been disclosed in Japanese Patent Application Laid-Open No. 4-149174, which is a method for obtaining a salt with an optically active tartaric acid (racemic). Body division) is known. However, this method is optical resolution using a salt, and even when complete resolution is possible, it is inevitable that an unnecessary steric amine compound remains.
[0005]
[Problems to be solved by the invention]
An object of the present invention is to provide a compound represented by the formula (4) useful as a raw material for producing a quinolone derivative (hereinafter referred to as compound (4). The same applies to compounds of other numbers). An object of the present invention is to provide a method for producing only a desired stereoisomer by an asymmetric reduction reaction using
[0006]
That is, the present invention relates to the formula (1)
[0007]
Embedded image
(In the formula, R represents a benzyl group, a trityl group, a benzhydryl group or a lower alkyl group. When the substituent R is a substituent having a benzene ring, the benzene ring may have a substituent. .N represents 2 or 3.)
A compound represented by
Formula (2), which is treated with a microorganism, a culture solution, or a treated microbial cell of a microorganism belonging to the genus Phaeocreopsis and having asymmetric reducing ability.
[0008]
Embedded image
(In the formula, R represents a benzyl group, a trityl group, a benzhydryl group or a lower alkyl group. When the substituent R is a substituent having a benzene ring, the benzene ring may have a substituent. .N represents 2 or 3.)
And a process for producing the compound represented by
[0009]
Furthermore, the present invention relates to the above process, wherein the compound of the formula (1) is a compound wherein R is a benzyl group and n is 2 or 3.
[0010]
Further, the present invention provides a compound represented by the formula (1):
Treated with microbial cells of a microorganism belonging to the genus Phaeocreopsis and having asymmetric reduction ability, a culture solution or a processed microbial cell,
A compound represented by the formula (2) is obtained, and diphenylphosphoryl azide is allowed to act on the compound represented by the formula (2).
[0011]
Embedded image
(In the formula, R represents a benzyl group, a trityl group, a benzhydryl group or a lower alkyl group. When the substituent R is a substituent having a benzene ring, the benzene ring may have a substituent. .N represents 2 or 3.)
Wherein the compound represented by the formula (3) is reduced and the compound represented by the formula (3) is reduced:
[0012]
Embedded image
(In the formula, R represents a benzyl group, a trityl group, a benzhydryl group or a lower alkyl group. When the substituent R is a substituent having a benzene ring, the benzene ring may have a substituent. .N represents 2 or 3.)
And a method for producing the compound represented by
[0013]
Further, the present invention relates to the above-mentioned production method, wherein the reduction of the compound represented by the formula (3) is reduction with a metal aluminum hydride compound or diborane.
[0014]
Furthermore, the present invention relates to the above-mentioned production method, wherein the compound of the formula (1) is a compound wherein R is a benzyl group and n is 2.
[0015]
The present invention will be described in detail below.
That is, the present invention provides a compound (1) which is reacted with a microorganism having an asymmetric reduction ability selected from microorganisms belonging to the genus Phaeocleoptis to obtain an optically active compound (2), To a compound (4).
[0016]
The substituent R in the compound represented by the formula (1) used in the present invention means a benzyl group, a trityl group, a benzhydryl group or a lower alkyl group. Here, when R is a benzyl group having a benzene ring as a partial structure, a trityl group, or a benzhydryl group, the benzene ring may further have a substituent. When there are a plurality of benzene rings, one or more benzene rings may be substituted. One or more substituents may be substituted on the benzene ring 1 by one or more. Examples of such a substituent on the benzene ring include alkyl groups such as methyl group, ethyl group, propyl group, butyl group, pentyl group and hexyl group, methoxyl group, ethoxyl group, propoxyl group, butoxyl group, pentoxyl group. Or a substituent selected from the group consisting of alkoxyl groups such as hexyloxy group, halogen atoms, and nitro group. The compound represented by the formula (1) can be prepared by a known method (see JP-A-3-95176 and JP-A-5-286933).
[0017]
In order to produce the compound (2) from the compound (1) by the method of the present invention, the production is carried out using a commercially available microorganism belonging to the genus Phaeocreopsis sp. do it. In this method, cells of a microorganism belonging to the genus Phaeocleoptis, a culture solution or a treated product of the microorganism can be used.
[0018]
Microbial cells are viable cells collected from a culture solution by centrifugation, filtration, or the like, or dried cells such as vacuum-dried cells, freeze-dried cells, and dried cells using an organic solvent. . Alternatively, a cell obtained by immobilizing cells on a water-insoluble carrier (eg, acrylamide gel) by a known method may be used.
[0019]
The culture solution of the microorganism is obtained by culturing the microorganism in an appropriate medium, and contains the grown microorganism cells and metabolites thereof.
[0020]
Microbial cell processed product, microbial cell extract or microbial cell ground product, and microbial cells are subjected to ultrasonic treatment, and further, they are fractionated by known methods such as chromatography and filtration. The components required for the asymmetric reduction treatment of the present invention are separated. The components required for the processing contained in this fraction may not be completely pure, and may contain other components as long as they do not hinder the reaction.
[0021]
A method for producing the compound represented by the formula (2) by the method of the present invention will be described. That is, the method may be carried out by first suspending the compound represented by the formula (1) in an appropriate buffer solution, then adding a cell, culture or treated product of a microorganism belonging to Phaeocreopsis, and treating with stirring.
[0022]
In this treatment, the treatment temperature is usually in the range of 5 ° C. to 60 ° C., preferably in the range of 20 ° C. to 40 ° C. The pH of the treatment liquid may be in the range of 4 to 9, and is preferably in the range of 5 to 7. The processing time is usually from 1 day to 3 days, and the processing liquid may be stirred.
[0023]
The concentration of the compound represented by the formula (1) used in the treatment solution may be between 0.1% and 5%, but is particularly preferably in the range of 0.1% to 0.5%. preferable. The amount of the culture solution of the microorganism, the microbial cells or the processed product of the microbial cells is not particularly limited, but is preferably 0.2 to 2 times the weight of the compound (1) in terms of the dry cell weight. It is.
[0024]
After completion of the above treatment, the treatment solution is filtered to remove bacterial cells, and then the target compound (2) can be isolated from the filtrate by using ordinary operations such as extraction and concentration under reduced pressure.
[0025]
In order to convert the compound (2) into the compound (3) which is an azide compound, a method of reacting diphenylphosphoryl azide is convenient. In the present invention, the reaction may be carried out using reaction conditions usually used for this reagent.
[0026]
The reduction for converting the compound (3) to the compound (4) uses a metal aluminum hydride compound such as lithium aluminum hydride and sodium bis (2-methoxyethoxy) aluminum hydride or a borohydride compound such as diborane. The amide moiety and the azide moiety of compound (3) may be reduced at the same time.
[0027]
【Example】
Hereinafter, the present invention will be described specifically with reference to Examples or Reference Examples, but the present invention is not limited thereto.
[0028]
[Reference Example 1]
100 ml of a liquid medium (pH 6.0) composed of glucose 4%, peptone 1%, dipotassium hydrogen phosphate 0.1% and potassium dihydrogen phosphate 0.1% is dispensed into a Sakaguchi flask and placed in an autoclave. And heat sterilized. The culture medium of the flask was inoculated with a bacterium of the genus Phaeocreopsis (JCM 1880), and cultured with shaking at 30 ° C. for 2 nights to obtain a cell culture solution.
[0029]
Example 1 Preparation of (R) -5- benzyl- 7 -hydroxy -4- oxo -5- azaspiro [2.4] heptane 5-benzyl-4,7-dioxo-5-azaspiro [2.4] Heptane (300 mg) was suspended in the culture solution (300 ml) obtained in the above Reference Example and stirred for 3 days. 100 ml of ethyl acetate was added to the reaction solution, and the cells were removed by filtration through celite. The aqueous layer was further extracted twice with 100 ml of ethyl acetate, the organic layer was dried, and the solvent was distilled off. The residue was subjected to silica gel chromatography to obtain 195 mg of the desired product (optical purity 99% ee). In addition, the analysis of the optical isomer was performed using HPLC.
[0030]
-Column used: Chiral Cell OJ (manufactured by Daicel Chemical Industries, Ltd.)
Mobile phase: n-hexane: isopropanol = 10: 1
-Flow rate: 0.8 ml / min, wavelength: 230 nm
[0031]
1 H-NMR (CDCl 3 ) δ:
0.88-1.18 (4H, m), 3.12-3.63 (3H, m), 3.93-4.06 (1H, m), 4.45 (2H, d, J = 2 Hz), 7.19-7.35 (5H, m).
[0032]
Example 2 Preparation of (R) -6- benzyl- 8 -hydroxy -5- oxo -6- azaspiro [3.4] octane 6-benzyl-5,8-dioxo-6-azaspiro [3.4] Octane (100 mg) was suspended in the culture solution (100 ml) obtained in the above Reference Example and stirred for 24 hours. Ethyl acetate (50 ml) was added to the reaction solution, and the cells were removed by celite filtration. The aqueous layer was further extracted twice with 50 ml of ethyl acetate, the organic layer was dried, and the solvent was distilled off. The residue was subjected to silica gel chromatography to obtain 80 mg of the desired product (optical purity: 99% ee). In addition, the analysis of the optical isomer was performed using HPLC similarly to Example 1.
[0033]
1 H-NMR (CDCl 3 ) δ:
1.82-1.61 (6H, m), 3.24-3.69 (3H, m), 3.96-4.11 (1H, m), 4.59 (2H, d, J = 2) Hz), 7.15-7.40 (5H, m).
[0034]
Example 3 Production of (S) -7- azido -5- benzyl -4- oxo -5- azaspiro [2.4] heptane 230 mg of diethyl azodicarboxylate and 340 mg of triphenylphosphine were dried. The residue was dissolved in 5 ml of tetrahydrofuran and stirred for 30 minutes under ice cooling. Next, a solution of (R) -5-benzyl-7-hydroxy-4-oxo-5-azaspiro [2.4] heptane (220 mg) and diphenylphosphoryl azide (360 mg) in anhydrous tetrahydrofuran was added dropwise and stirred overnight. The solvent was distilled off, and the residue was subjected to silica gel chromatography to obtain 150 mg of the title compound as an oily compound.
[0035]
1 H-NMR (CDCl 3 ) δ:
0.85-1.51 (4H, m), 3.23-3.83 (3H, m), 4.60 (2H, d, J = 3 Hz), 7.26-7.30 (5H, m) m).
IR (KBr): 2100 cm −1 (N 3 )
[0036]
Example 4 Preparation of (S) -7- amino - 5 - benzyl - 5 - azaspiro [2.4] heptane Lithium aluminum hydride in 3 ml of tetrahydrofuran solution (1.0 M / L) was stirred under ice-cooling (S). ) -7-Azido-5-benzyl-4-oxo-5-azaspiro [2.4] heptane (140 mg) was dissolved in anhydrous tetrahydrofuran (5 ml) and added dropwise, followed by stirring under heating and reflux for 1 hour. The reaction solution was cooled on ice, 0.2 ml of water and 0.2 ml of a 10% aqueous sodium hydroxide solution were added dropwise, and the mixture was stirred at room temperature for 30 minutes. The insolubles were removed by filtration, the filtrate was concentrated, and the residue was subjected to silica gel chromatography to obtain 92 mg (98% ee of optical purity) of the title compound. In addition, the analysis of the optical isomer was performed using HPLC after derivatizing the amine into the dinitrobenzoyl form.
[0037]
-Column used: Sumichiral OA-4600 (manufactured by Sumitomo Chemical Co., Ltd.)
Mobile phase: n-hexane: ethylene dichloride: ethanol: trifluoroacetic acid = 80: 20: 5: 0.2
・ Flow rate: 1.2 ml / min, wavelength: 254 nm
[0038]
1 H-NMR (CDCl 3 ) δ:
0.26-0.96 (4H, m), 2.20-3.16 (5H, m), 3.61 (2H, s), 7.33 (5H, bs)
[0039]
【The invention's effect】
According to the method of the present invention, the reaction can be carried out under mild conditions, and since a side reaction hardly occurs during the reaction, a highly pure optically active compound (2) can be obtained. Further, the obtained compound (2) can be easily derived to compound (4) via compound (3).
Claims (6)
で示される化合物を、
ファエオクレオプシス属に属し不斉還元能を有する微生物の菌体、培養液または微生物菌体処理物で処理することを特徴とする、式(2)
で示される化合物の製造法Equation (1)
A compound represented by
Formula (2), which is treated with a microorganism, a culture solution, or a treated microbial cell of a microorganism belonging to the genus Phaeocreopsis and having asymmetric reducing ability.
Method for producing compound represented by
で示される化合物を、ファエオクレオプシス属に属し不斉還元能を有する微生物の菌体、培養液または微生物菌体処理物で処理し、式(2)
で示される化合物を得、この式(2)で示される化合物にジフェニルホスホリルアジドを作用させ、式(3)
で示される化合物を得、この式(3)で示される化合物を還元することを特徴とする式(4)
で示される化合物の製造法Equation (1)
The compound represented by the formula (2) is treated with a microbial cell, a culture solution or a processed microbial cell of a microorganism belonging to the genus Phaeocleoptis and having asymmetric reduction ability;
The compound represented by the formula (2) is reacted with diphenylphosphoryl azide to give a compound represented by the formula (3)
Wherein the compound represented by the formula (3) is reduced and the compound represented by the formula (3) is reduced:
Method for producing compound represented by
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30255694A JP3596919B2 (en) | 1994-12-07 | 1994-12-07 | Method for producing high-purity optically active compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30255694A JP3596919B2 (en) | 1994-12-07 | 1994-12-07 | Method for producing high-purity optically active compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08157454A JPH08157454A (en) | 1996-06-18 |
| JP3596919B2 true JP3596919B2 (en) | 2004-12-02 |
Family
ID=17910406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP30255694A Expired - Fee Related JP3596919B2 (en) | 1994-12-07 | 1994-12-07 | Method for producing high-purity optically active compounds |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3596919B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105906545B (en) * | 2016-05-06 | 2018-06-29 | 广州康瑞泰药业有限公司 | A kind of preparation method for synthesizing sitafloxacin intermediate (7S) -5- azaspiros [2.4] heptane -7- carbamates |
| CN109232530B (en) * | 2018-10-25 | 2020-05-22 | 苏州东瑞制药有限公司 | Preparation method of sitafloxacin hydrate |
-
1994
- 1994-12-07 JP JP30255694A patent/JP3596919B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08157454A (en) | 1996-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3789938B2 (en) | Racemic resolution of primary and secondary heteroatom-substituted amines by enzyme-catalyzed acylation | |
| EA010305B1 (en) | Stereoselective bioconversion of aliphatic dinitriles into cyano carboxylic acids | |
| EP2284174B1 (en) | Intermediates for the preparation of benzoxazine derivatives and process for their preparation | |
| RU2226550C2 (en) | Method for enzymatic preparing non-proteinogenic l-amino acids | |
| JP3596919B2 (en) | Method for producing high-purity optically active compounds | |
| JP2013223458A (en) | Method for manufacturing optically active triptycene derivative | |
| EP1367132B1 (en) | Process for preparation of optically active propoxyaniline derivatives | |
| CN101321875B (en) | Preparation of (R)- and (S)-4-(1- Ammonium ethyl) methyl benzoate sulfate method | |
| JPH01141600A (en) | Production of optically active 3-hydroxypyrrolidine derivative | |
| JP5329973B2 (en) | From racemic 4- (1-aminoethyl) benzoic acid methyl ester to (R)-and (S) -4- (1-ammoniumethyl) by enantioselective acylation using a lipase catalyst followed by precipitation with sulfuric acid. Method for preparing benzoic acid methyl ester sulfate | |
| JP4492765B2 (en) | Method for producing L-allysine acetal | |
| JP2698627B2 (en) | Method for producing optically active amines and derivatives thereof | |
| JP3452378B2 (en) | Production method of halogenated compounds | |
| WO2010019469A2 (en) | Preparation of (s)-2-aminobutyric acid | |
| JP2887524B2 (en) | Optical resolution method using microorganisms | |
| JP2813342B2 (en) | Method for producing optically active 3-hydroxypyrrolidine derivative | |
| JP4652577B2 (en) | Method for producing optically active 3,3,3-trifluoromethyl-2-alkylpropionic acid derivative | |
| JP4195521B2 (en) | Optically active-substituted nitrogen-containing cyclic compounds, production raw materials thereof, and production methods thereof | |
| JP4544385B2 (en) | Process for producing optically active 2,6-diaminoheptanoic acid | |
| EP1311700B1 (en) | Production process of l-phenylalanine derivatives by microorganisms | |
| JP2007117034A (en) | Method for producing optically active nipecotic acid compound | |
| JPH07303496A (en) | Production of optically active (s)-2-phenyl-3-methyl butylamine | |
| JP2001163841A (en) | Method for producing optically active 2-(2,3,4- trihalogenoanilino)-propionic acid derivative | |
| JP2007074942A (en) | Process for producing optically active penicillamine | |
| JP2007252238A (en) | Process for producing optically active nitrogen-containing cyclic compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Effective date: 20040608 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040622 |
|
| A521 | Written amendment |
Effective date: 20040622 Free format text: JAPANESE INTERMEDIATE CODE: A821 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Effective date: 20040825 Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A521 | Written amendment |
Effective date: 20040803 Free format text: JAPANESE INTERMEDIATE CODE: A821 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040907 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080917 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 4 Free format text: PAYMENT UNTIL: 20080917 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080917 Year of fee payment: 4 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080917 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090917 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 5 Free format text: PAYMENT UNTIL: 20090917 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 6 Free format text: PAYMENT UNTIL: 20100917 |
|
| LAPS | Cancellation because of no payment of annual fees |